Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID EXTEND: Personalized Antiplatelet Therapy Post-MI
NCT03729401Phase 4Terminated
- Sponsor
- University of Ottawa Heart Institute
- Start
- Aug 2019
- Primary completion
- Mar 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of ticagrelor, clopidogrel, aspirin in myocardial infarction (MI), coronary artery disease (CAD), sponsored by University of Ottawa Heart Institute. Started Aug 2019; status: terminated.
02
Drugs
ticagrelorclopidogrelaspirin
03
Conditions
myocardial infarction (MI)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03729401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03729401.